World Therapy: Cervical Cancer – Pipeline Review, H1 2012

  • February 2014
  • -
  • Global Markets Direct
  • -
  • 274 pages

This report provides data on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. 'Cervical Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Cervical Cancer.
- A review of the Cervical Cancer products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Cervical Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Cervical Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents
Data table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global March kets Direct Report Coverage 9
Cervical Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Cervical Cancer 11
Cervical Cancer Therapeutics under Development by Firms 13
Cervical Cancer Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Discovery and Pre-Clinical Stage Products 25
Comparative Analysis 25
Cervical Cancer Therapeutics - Products under Development by Firms 26
Cervical Cancer Therapeutics - Products under Investigation by Universities/Institutes 27
Companies Involved in Cervical Cancer Therapeutics Development 31
Helix BioPharma Corp. 31
Sanofi-Aventis 32
GlaxoSmithKline plc 33
Inovio Biomedical Corporation 34
Merck and Co., Inc. 35
YM BioSciences Inc. 36
MediGene AG 37
November artis AG 38
Taiho Pharmaceutical Co., Ltd. 39
Zeria Pharmaceutical Co Ltd 40
CEL-SCI Corporation 41
Advaxis, Inc. 42
3SBio Inc. 43
Neogenix Oncology Corporation 44
Dendreon Corporation 45
Transgene SA 46
Antigen Express, Inc. 47
Nutri Pharma ASA 48
ApoImmune, Inc. 49
PDS Biotechnology Corporation 50
BT PHARMA 51
PharmaMarch, S.A. 52
Genetic Immunity, LLC 53
Advanced Cancer Therapeutics 54
Eurofarma 55
ISA Pharmaceuticals B.V. 56
Cervical Cancer - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 64
Z-100 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
V503 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Paclitaxel + Cisplatin - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Cisplatin + Vinorelbine Ditartrate - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Tirapazamine + Cisplatin + Radiation Therapy - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
Gemcitabine + Cisplatin - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
Gemcitabine + Cisplatin - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
HPV16/18 VLP Vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
Paclitaxel + Carboplatin - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
Cisplatin + Paclitaxel - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
S-1 + Cisplatin - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
Epoetin alfa + Cisplatin + Brachytherapy + Radiation therapy - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
Gardasil - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
Topotecan + Paclitaxel - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
Bevacizumab + Paclitaxel + Topotecan - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
Topotecan + Cisplatin - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
Carboplatin + Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 89
Cisplatin + Radiation Therapy - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
Methotrexate + Vinblastine + Doxorubicin + Cisplatin - Drug Profile 92
Product Description 92
Mechanism of Action 92
RandD Progress 92
Paclitaxel + Cisplatin - Drug Profile 94
Product Description 94
Mechanism of Action 94
RandD Progress 94
Paclitaxel + Topotecan - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
Paclitaxel + Topotecan - Drug Profile 96
Product Description 96
Mechanism of Action 96
RandD Progress 96
Gendicine + Radiation Therapy - Drug Profile 97
Product Description 97
Mechanism of Action 97
RandD Progress 97
Topotecan + Cisplatin - Drug Profile 98
Product Description 98
Mechanism of Action 98
RandD Progress 98
Cisplatin + Vincristine - Drug Profile 99
Product Description 99
Mechanism of Action 99
RandD Progress 99
Cisplatin + Hyperthermia Therapy + Radiation Therapy - Drug Profile 100
Product Description 100
Mechanism of Action 100
RandD Progress 100
Platinex + Radiation Therapy - Drug Profile 101
Product Description 101
Mechanism of Action 101
RandD Progress 101
Fluorouracil + Radiation Therapy - Drug Profile 102
Product Description 102
Mechanism of Action 102
RandD Progress 102
Cisplatin + Gemcitabine - Drug Profile 103
Product Description 103
Mechanism of Action 103
RandD Progress 103
Paclitaxel + Cispaltin + Radiotherapy - Drug Profile 104
Product Description 104
Mechanism of Action 104
RandD Progress 104
Cisplatin + Brachytherapy + Radiation Therapy - Drug Profile 106
Product Description 106
Mechanism of Action 106
RandD Progress 106
Uracil-Tegafur + Radiation Therapy - Drug Profile 107
Product Description 107
Mechanism of Action 107
RandD Progress 107
Cisplatin + Radiation Therapy - Drug Profile 108
Product Description 108
Mechanism of Action 108
RandD Progress 108
Cisplatin + Vinorelbine + Nimotuzumab - Drug Profile 109
Product Description 109
Mechanism of Action 109
RandD Progress 109
S-1 - Drug Profile 110
Product Description 110
Mechanism of Action 110
RandD Progress 110
Cervical Cancer Therapeutics - Drug Profile Updates 111
Cervical Cancer Therapeutics - Discontinued Products 113
Cervical Cancer Therapeutics - Dormant Products 114
Cervical Cancer - Product Development Milestones 118
Featured News and Press Releases 118
January 25, 2012: Advaxis Reports Preliminary Safety And Survival Data from Phase II Trial In Recurrent/Refractory Cervical Cancer 118
January 11, 2012: Advaxis Begins Dosing For GOG US Cervical Cancer Study Evaluating ADXS-HPV 118
December 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 119
November 09, 2011: Data Published In The Lancet Oncology Supports High Efficacy Previously Demonstrated By Cervarix Against Precancerous Cervical Lesions Caused By HPV 16 and 18 120
July 01, 2011: Merck Receives Approval To March ket GARDASIL In Japan 121
April 26, 2011: Merck Receives Health Canada Approval For Gardasil For Women Up To Age 45 122
April 25, 2011: Rwanda, Merck And QIAGEN Launch Cervical Cancer Prevention Program Incorporating Both HPV Vaccination And HPV Testing In Africa 122
April 06, 2011: U.S. Prescribing Information for GARDASIL Updated; Indication Not Granted for Use in Adult Women 123
March 07, 2011: Inovio Pharmaceuticals Enters Phase II Clinical Trial With SynCon DNA Vaccine For Cervical Dysplasia Caused by HPV 124
November 24, 2010: Advaxis India Begins Dosing In Cervix Cancer Trial With ADXS11-001 124
Appendix 126
Methodology 126
Coverage 126
Secondary Research 126
Primary Research 126
Expert Panel Validation 127
Contact Us 127
Disclaimer 127

List of Tables

Number of Products Under Development for Cervical Cancer, H1 2012 11
Products under Development for Cervical Cancer - Comparative Analysis, H1 2012 12
Number of Products under Development by Firms, H1 2012 14
Number of Products under Development by Firms, H1 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2012 17
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 21
Comparative Analysis by Late Stage Development, H1 2012 22
Comparative Analysis by Mid Clinical Stage Development, H1 2012 23
Comparative Analysis by Early Clinical Stage Development, H1 2012 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 25
Products under Development by Firms, H1 2012 26
Products under Investigation by Universities/Institutes, H1 2012 27
Helix BioPharma Corp., H1 2012 31
Sanofi-Aventis, H1 2012 32
GlaxoSmithKline plc, H1 2012 33
Inovio Biomedical Corporation, H1 2012 34
Merck and Co., Inc., H1 2012 35
YM BioSciences Inc., H1 2012 36
MediGene AG, H1 2012 37
November artis AG, H1 2012 38
Taiho Pharmaceutical Co., Ltd., H1 2012 39
Zeria Pharmaceutical Co Ltd, H1 2012 40
CEL-SCI Corporation, H1 2012 41
Advaxis, Inc., H1 2012 42
3SBio Inc., H1 2012 43
Neogenix Oncology Corporation, H1 2012 44
Dendreon Corporation, H1 2012 45
Transgene SA, H1 2012 46
Antigen Express, Inc., H1 2012 47
Nutri Pharma ASA, H1 2012 48
ApoImmune, Inc., H1 2012 49
PDS Biotechnology Corporation, H1 2012 50
BT PHARMA, H1 2012 51
PharmaMarch, S.A., H1 2012 52
Genetic Immunity, LLC, H1 2012 53
Advanced Cancer Therapeutics, H1 2012 54
Eurofarma, H1 2012 55
ISA Pharmaceuticals B.V., H1 2012 56
Assessment by Monotherapy Products, H1 2012 57
Assessment by Combination Products, H1 2012 58
Assessment by Stage and Route of Administration, H1 2012 60
Assessment by Stage and Molecule Type, H1 2012 63
Cervical Cancer Therapeutics - Drug Profile Updates 111
Cervical Cancer Therapeutics - Discontinued Products 113
Cervical Cancer Therapeutics - Dormant Products 114

List of Figures

Number of Products under Development for Cervical Cancer, H1 2012 11
Products under Development for Cervical Cancer - Comparative Analysis, H1 2012 12
Products under Development by Firms, H1 2012 13
Products under Investigation by Universities/Institutes, H1 2012 16
Late Stage Products, H1 2012 22
Mid Clinical Stage Products, H1 2012 23
Early Clinical Stage Products, H1 2012 24
Discovery and Pre-Clinical Stage Products, H1 2012 25
Assessment by Monotherapy Products, H1 2012 57
Assessment by Combination Products, H1 2012 58
Assessment by Route of Administration, H1 2012 59
Assessment by Stage and Route of Administration, H1 2012 60
Assessment by Molecule Type, H1 2012 61
Assessment by Stage and Molecule Type, H1 2012 62

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.